125 related articles for article (PubMed ID: 36842710)
1. Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress.
Jiang X; Ma Y; Wang T; Zhou H; Wang K; Shi W; Qin L; Guan J; Li L; Long B; Wang J; Guan X; Ye H; Yang J; Yu Z; Jiao Z
Gastroenterology; 2023 Jun; 164(7):1232-1247. PubMed ID: 36842710
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-conjugating enzyme E2T(UBE2T) promotes colorectal cancer progression by facilitating ubiquitination and degradation of p53.
Wu M; Li X; Huang W; Chen Y; Wang B; Liu X
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101493. PubMed ID: 32736946
[TBL] [Abstract][Full Text] [Related]
3. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
[TBL] [Abstract][Full Text] [Related]
4. UBE2T-mediated Akt ubiquitination and Akt/β-catenin activation promotes hepatocellular carcinoma development by increasing pyrimidine metabolism.
Zhu Z; Cao C; Zhang D; Zhang Z; Liu L; Wu D; Sun J
Cell Death Dis; 2022 Feb; 13(2):154. PubMed ID: 35169125
[TBL] [Abstract][Full Text] [Related]
5. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW
Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028
[TBL] [Abstract][Full Text] [Related]
6. UBE2T promotes glioblastoma malignancy through ubiquitination-mediated degradation of RPL6.
Tao X; Wu X; Zhou P; Yu X; Zhao C; Peng X; Zhang K; Shen L; Peng J; Yang L
Cancer Sci; 2023 Feb; 114(2):521-532. PubMed ID: 36156329
[TBL] [Abstract][Full Text] [Related]
7. mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53
Qiu J; Feng M; Yang G; Cao Z; Liu Y; You L; Zhang T
Cancer Lett; 2023 Feb; 554():216020. PubMed ID: 36442772
[TBL] [Abstract][Full Text] [Related]
8. Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer.
Husain K; Centeno BA; Chen DT; Hingorani SR; Sebti SM; Malafa MP
Cancer Prev Res (Phila); 2013 Oct; 6(10):1074-83. PubMed ID: 23963802
[TBL] [Abstract][Full Text] [Related]
9. Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.
Plassmeier L; Knoop R; Waldmann J; Kesselring R; Buchholz M; Fichtner-Feigl S; Bartsch DK; Fendrich V
Langenbecks Arch Surg; 2013 Oct; 398(7):989-96. PubMed ID: 23989613
[TBL] [Abstract][Full Text] [Related]
10. UBE2T promotes autophagy via the p53/AMPK/mTOR signaling pathway in lung adenocarcinoma.
Zhu J; Ao H; Liu M; Cao K; Ma J
J Transl Med; 2021 Aug; 19(1):374. PubMed ID: 34461934
[TBL] [Abstract][Full Text] [Related]
11. UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53.
Liu LP; Yang M; Peng QZ; Li MY; Zhang YS; Guo YH; Chen Y; Bao SY
Biochem Biophys Res Commun; 2017 Nov; 493(1):20-27. PubMed ID: 28935368
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis.
Kaushik G; Seshacharyulu P; Rauth S; Nallasamy P; Rachagani S; Nimmakayala RK; Vengoji R; Mallya K; Chirravuri-Venkata R; Singh AB; Foster JM; Ly QP; Smith LM; Lele SM; Malafa MP; Jain M; Ponnusamy MP; Batra SK
Oncogene; 2021 Jan; 40(4):848-862. PubMed ID: 33288882
[TBL] [Abstract][Full Text] [Related]
13. Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan.
Rodriguez Lanzi C; Wei R; Luo D; Mackenzie GG
Neoplasia; 2022 Feb; 24(2):133-144. PubMed ID: 34968866
[TBL] [Abstract][Full Text] [Related]
14. Predicting Gemcitabine Delivery by
Russell J; Grkovski M; O'Donoghue IJ; Kalidindi TM; Pillarsetty N; Burnazi EM; Kulick A; Bahr A; Chang Q; LeKaye HC; de Stanchina E; Yu KH; Humm JL
J Nucl Med; 2021 Feb; 62(2):195-200. PubMed ID: 32646874
[No Abstract] [Full Text] [Related]
15. UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation.
Sun J; Zhu Z; Li W; Shen M; Cao C; Sun Q; Guo Z; Liu L; Wu D
J Exp Clin Cancer Res; 2020 Oct; 39(1):222. PubMed ID: 33087136
[TBL] [Abstract][Full Text] [Related]
16. Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis.
Tiwari A; Tashiro K; Dixit A; Soni A; Vogel K; Hall B; Shafqat I; Slaughter J; Param N; Le A; Saunders E; Paithane U; Garcia G; Campos AR; Zettervall J; Carlson M; Starr TK; Marahrens Y; Deshpande AJ; Commisso C; Provenzano PP; Bagchi A
Gastroenterology; 2020 Nov; 159(5):1882-1897.e5. PubMed ID: 32768595
[TBL] [Abstract][Full Text] [Related]
17. A ketogenic diet in combination with gemcitabine increases survival in pancreatic cancer KPC mice.
Cortez NE; Rodriguez Lanzi C; Hong BV; Xu J; Wang F; Chen S; Ramsey JJ; Pontifex MG; Müller M; Vauzour D; Vahmani P; Hwang CI; Matsukuma K; Mackenzie GG
Cancer Res Commun; 2022 Sep; 2(9):951-965. PubMed ID: 36382086
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin-conjugating enzyme E2T knockdown suppresses hepatocellular tumorigenesis
Guo J; Wang M; Wang JP; Wu CX
World J Gastroenterol; 2019 Nov; 25(43):6386-6403. PubMed ID: 31798276
[TBL] [Abstract][Full Text] [Related]
19. Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Li H; Yang AL; Chung YT; Zhang W; Liao J; Yang GY
Carcinogenesis; 2013 Sep; 34(9):2090-8. PubMed ID: 23689354
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells.
Ueki T; Park JH; Nishidate T; Kijima K; Hirata K; Nakamura Y; Katagiri T
Cancer Res; 2009 Nov; 69(22):8752-60. PubMed ID: 19887602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
